PMID- 20510503
OWN - NLM
STAT- MEDLINE
DCOM- 20101004
LR  - 20181201
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 297
IP  - 1
DP  - 2010 Nov 1
TI  - RXRgamma and PPARgamma ligands in combination to inhibit proliferation and 
      invasiveness in colon cancer cells.
PG  - 65-74
LID - 10.1016/j.canlet.2010.04.026 [doi]
AB  - Nuclear retinoid X receptors (RXRs) and peroxisome proliferator-activated 
      receptors (PPARs are potential candidates as drug target for cancer prevention 
      and treatment. We investigated if the rexinoid 6-OH-11-O-hydroxyphenantrene (IIF) 
      potentiates the antitumoral properties of PPARgamma ligands as ciglitazone and 
      pioglitazone, on two colon cancer cell lines: HCA-7 and HCT-116. Drugs inhibited 
      cell growth and induced apoptosis synergistically. The combination resulted in a 
      decrease of cyclooxigenase-2, metalloproteinases-2 and -9 expression level and 
      activity while PPARgamma, RXRgamma and tissue inhibitors of metalloproteinase-1 
      and -2 expression were increased. Finally, IIF potentiated PPAR transcriptional 
      activity by enhancement of peroxisome proliferator response elements 
      transactivation.
CI  - 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Papi, Alessio
AU  - Papi A
AD  - Department of Experimental Evolutionary Biology, University of Bologna, Italy. 
      alessio.papi2@unibo.it
FAU - Rocchi, Paola
AU  - Rocchi P
FAU - Ferreri, Anna Maria
AU  - Ferreri AM
FAU - Orlandi, Marina
AU  - Orlandi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100526
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (IIF compound)
RN  - 0 (Ligands)
RN  - 0 (PPAR gamma)
RN  - 0 (Retinoid X Receptor gamma)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - U8QXS1WU8G (ciglitazone)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Movement/*drug effects
MH  - Cell Proliferation/*drug effects
MH  - Cell Survival/drug effects
MH  - Colonic Neoplasms/genetics/metabolism/*pathology
MH  - Cyclooxygenase 2/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - HCT116 Cells
MH  - Humans
MH  - Ligands
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Neoplasm Invasiveness
MH  - PPAR gamma/*agonists/genetics/metabolism
MH  - Pioglitazone
MH  - Response Elements/drug effects
MH  - Retinoid X Receptor gamma/*agonists/metabolism
MH  - Thiazolidinediones/pharmacology
MH  - Tissue Inhibitor of Metalloproteinase-1/metabolism
MH  - Tissue Inhibitor of Metalloproteinase-2/metabolism
MH  - Transcriptional Activation/drug effects
MH  - Tretinoin/analogs & derivatives/pharmacology
EDAT- 2010/06/01 06:00
MHDA- 2010/10/05 06:00
CRDT- 2010/06/01 06:00
PHST- 2010/03/15 00:00 [received]
PHST- 2010/04/21 00:00 [revised]
PHST- 2010/04/27 00:00 [accepted]
PHST- 2010/06/01 06:00 [entrez]
PHST- 2010/06/01 06:00 [pubmed]
PHST- 2010/10/05 06:00 [medline]
AID - S0304-3835(10)00241-7 [pii]
AID - 10.1016/j.canlet.2010.04.026 [doi]
PST - ppublish
SO  - Cancer Lett. 2010 Nov 1;297(1):65-74. doi: 10.1016/j.canlet.2010.04.026. Epub 
      2010 May 26.